[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100188646":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":24,"responsibleParty":48,"collaborators":51,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":10,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Cologne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Emerging fungal infections",null,"Web-based registry of invasive infections by emerging fungi",[13],{"name":14,"affiliation":15,"role":16},"Oliver A. Cornely, Professor","University Hospital of Cologne","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Oliver A Cornely, Prof.","CONTACT","+49 221 478","6494","oliver.cornely@uk-koeln.de",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"University Hospital Cologne","RECRUITING","Cologne","North Rhine-Westphalia","50937","Germany","DE",{"type":34,"coordinates":35},"Point",[36,37],6.95,50.93333,{"lat":37,"lon":36},[40,41,45],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},{"name":42,"role":20,"phone":21,"phoneExt":43,"email":44},"Danila Seidel, PhD","97343","danila.seidel@uk-koeln.de",{"name":46,"role":47,"phone":10,"phoneExt":10,"email":10},"Philipp Köhler, MD","SUB_INVESTIGATOR",{"type":16,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Oliver Cornely, MD","Dr. med.",[52,55,57,59,61],{"name":53,"class":54},"Pfizer","INDUSTRY",{"name":56,"class":54},"Basilea Pharmaceutica",{"name":58,"class":54},"Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",{"name":60,"class":54},"F2G Biotech GmbH",{"name":62,"class":54},"Matinas Biopharma, Inc","100188646","fungiscope---a-global-emerging-fungal-infection-registry-100188646",false,"NCT01731353","FungiScope - A Global Emerging Fungal Infection Registry","FungiScope","Inclusion Criteria:\n\n* Cultural, histopathological, antigen or DNA evidence of invasive fungal infection\n\nExclusion Criteria:\n\n* Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci\n* Endemic fungal infection such as coccidioidomycosis or histoplasmosis\n* Colonisation or other non-invasive infection","ALL",{"count":72,"type":73},1000,"ESTIMATED","OBSERVATIONAL","The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.",[77],"Invasive Fungal Disease",[79,80],"invasive fungal infection","Web-based registry","2023-12-04",{"date":83,"type":84},"2023-12-05","ACTUAL",{"date":86,"type":10},"2003-03",{"date":88,"type":73},"2026-12",{"name":5,"class":6},1]